TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Essex Bio-Technology ( (HK:1061) ) has provided an update.
Essex Bio-Technology Limited has announced that its Biologics License Application for HLX04-O, an anti-VEGF ophthalmic injection developed for the treatment of wet-AMD, has been accepted by the Centre for Drug Evaluation in China. This development is significant as there is currently no approved bevacizumab product for wet-AMD in the Chinese market, where sales for similar treatments reached approximately RMB4.9 billion in 2024. The acceptance of this application marks a critical step in the potential commercialization of HLX04-O, which could enhance Essex Bio-Technology’s market positioning and offer a new treatment option for wet-AMD patients.
More about Essex Bio-Technology
Essex Bio-Technology Limited operates in the bio-pharmaceutical industry, focusing on the development and commercialization of innovative therapies. The company specializes in ophthalmic drugs, particularly targeting conditions such as exudative (wet) age-related macular degeneration (wet-AMD).
Average Trading Volume: 1,622,508
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.02B
Learn more about 1061 stock on TipRanks’ Stock Analysis page.